1.Stem cells and repair of injured retina
yong, LIU ; dong-fu, FENG ; zhi-an, ZHU
Journal of Shanghai Jiaotong University(Medical Science) 2006;0(02):-
Recently,the progress in employing transplanting stem cells to cure injured retina is very fast and has been continuously yielding exciting results.Various sources are used in the studies,including retina-derived cells such as M?ller cells and ciliary body cells,and non-retina-derived cells such as embryonic stem cells and brain-derived stem cells.This review briefly discusses the recent progress of these studies.
2.Advance in biomarkers of lung cancer in diagnosis and targeted therapy.
Jing ZHANG ; Zhi-yong LIANG ; Xuan ZENG ; Tong-hua LIU
Chinese Journal of Pathology 2009;38(8):564-567
Acid Anhydride Hydrolases
;
metabolism
;
Apoptosis
;
Biomarkers, Tumor
;
metabolism
;
Caspases
;
metabolism
;
Cell Adhesion Molecules
;
metabolism
;
Chromosome Deletion
;
Drug Delivery Systems
;
GPI-Linked Proteins
;
metabolism
;
Humans
;
Hyaluronoglucosaminidase
;
metabolism
;
In Situ Hybridization, Fluorescence
;
methods
;
Lung Neoplasms
;
diagnosis
;
drug therapy
;
genetics
;
metabolism
;
Neoplasm Proteins
;
metabolism
;
Neoplasm Staging
;
Receptor, Epidermal Growth Factor
;
metabolism
;
Vascular Endothelial Growth Factor A
;
metabolism
3.Verification and improvement of heaven-penetrating cooling needling at Yuji (LU 10) for pharyngitis.
Chinese Acupuncture & Moxibustion 2013;33(8):752-752
Acupuncture Points
;
Acupuncture Therapy
;
Adolescent
;
Adult
;
Aged
;
Child
;
Female
;
Humans
;
Male
;
Middle Aged
;
Pharyngitis
;
therapy
;
Young Adult
4.Recent advances of nasal natural killer/T-cell lymphoma.
Yong LIU ; Hai-yu YANG ; Ming-zhi LU
Chinese Journal of Pathology 2005;34(12):809-812
5.Advance in pulmonary adenocarcinoma with micropapillary pattern.
Jing ZHANG ; Zhi-yong LIANG ; Tong-hua LIU
Chinese Journal of Pathology 2011;40(3):202-205
Adenocarcinoma
;
drug therapy
;
genetics
;
metabolism
;
pathology
;
surgery
;
Adenocarcinoma, Bronchiolo-Alveolar
;
drug therapy
;
genetics
;
metabolism
;
pathology
;
surgery
;
Adenocarcinoma, Papillary
;
metabolism
;
pathology
;
Cadherins
;
metabolism
;
Diagnosis, Differential
;
Genes, erbB-1
;
genetics
;
Humans
;
Lung Neoplasms
;
drug therapy
;
genetics
;
metabolism
;
pathology
;
surgery
;
Lymphatic Metastasis
;
Mucin-1
;
metabolism
;
Mutation
;
Neoplasm Invasiveness
;
beta Catenin
;
metabolism
7.The application of hepatectomy occlusion technology.
Zhi-yong HUANG ; Yang-an LIU ; Xiao-ping CHEN
Chinese Journal of Surgery 2012;50(6):485-487
Hepatectomy
;
methods
;
Humans
;
Liver
;
blood supply
8.Recent advances of pancreatic cancer.
Wen-ze WANG ; Zhi-yong LIANG ; Tong-hua LIU
Chinese Journal of Pathology 2007;36(1):53-55
9.Prostate health index in predicting the results of prostate biopsy for prostate cancer: a meta-analysis.
Yan LIU ; Yong XU ; Zhi-Hong ZHANG ; Kuo YANG
National Journal of Andrology 2014;20(8):723-729
OBJECTIVETo systematically evaluate prostate health index (PHI) in predicting the results of prostate biopsy in the diagnosis of prostate cancer.
METHODSWe retrieved the literature relevant to the value of PHI in predicting prostate cancer at prostate biopsy published from the inception to February 2014 in the databanks of PubMed (1966 - 2014), CNKI (1982 - 2014), VIP (1989 - 2014), and Cochrane Library (1999 - 2014). According to the inclusion and exclusion criteria and retrieval strategies, we extracted the data, evaluated the quality of the included literature, and performed meta-analysis using the Meta-Disc 1.4 software.
RESULTSTotally, 64 articles were identified, of which 52 were excluded and 12 included with 1 430 cases of prostate cancer and 2 159 normal or BPH controls. There was heterogeneity among the included studies. Based on the random effect model, in predicting the results of prostate biopsy in the diagnosis of prostate cancer, serum PHI exhibited a pooled sensitivity of 55.1% (95% CI: 0.525 - 0.577), a pooled specificity of 71.5% (95% CI: 0.695 - 0.734), a positive likelihood ratio (P-LR) of 2.379 (95% CI: 1.922 - 2.943), a negative likelihood ratio (N-LR) of 0.515 (95% CI: 0.428 - 0.619), a diagnosis odds ratio (DOR) of 5.268 (95% CI: 3.870 - 7.170), a summary receiver operating characteristic curve--area under the curve (SROC AUC) of 0.7578, and a Q * index of 0.6999.
CONCLUSIONSerum PHI plays a role of auxiliary diagnosis in detecting prostate cancer and can be used in the prediction of the results of prostate biopsy.
Aged ; Biopsy, Needle ; Humans ; Male ; Middle Aged ; Prostate ; pathology ; Prostatic Neoplasms ; diagnosis ; pathology
10.Relationship between Epstein-Barr virus and breast tumors.
Yong LIU ; Si-si FAN ; Ming-zhi LU
Chinese Journal of Pathology 2008;37(4):269-271